CLRB News Alert Cellectar Biosciences Inc. (CLRB) 2.64 09/20/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cellectar Biosciences Inc. (CLRB) 2.64 $CLRB

Cellectar Biosciences Announces Participation in Two Upcoming Investor Conferences in September
GlobeNewswire - Fri Sep 05, 8:46AM CDT
Rodman & Renshaw 16 Annual Global Investment Conference on September 9, 2014

Cellectar Biosciences Announces Acceptance of Investigational New Drug Application to Evaluate I-131-CLR1404 in Clinical Trials in Relapsed or Refractory Multiple Myeloma
GlobeNewswire - Thu Sep 04, 7:35AM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB), announced today that the U.S. Food & Drug Administration (FDA) has accepted the Company's investigational new drug (IND) application to begin clinical study of I-131-CLR1404, a highly-selective, cancer-targeting radiopharmaceutical, in patients with relapsed or refractory multiple myeloma, an incurable cancer of plasma cells.

Cellectar Biosciences Reports Second Quarter 2014 Financial Results and Recent Highlights
GlobeNewswire - Wed Aug 20, 3:15PM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, is providing an overview of its development programs and financial results for the second quarter 2014.

Cellectar Biosciences Announces Closing of Public Offering and Partial Exercise of Underwriter's Over-Allotment Option
GlobeNewswire - Wed Aug 20, 3:13PM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced the closing of an underwritten public offering of 3,333,333 shares of its common stock at a per share price of $3.75 and warrants to purchase up to the same number of shares of common stock at a per warrant price of $0.01; plus the issuance of approximately an additional 1,110,000 shares and warrants in consideration of the cancellation of $4,000,000 principal amount of convertible debentures plus accrued interest. The warrants have an exercise price of $4.68 per share, are immediately exercisable and expire in August 2019.

Cellectar Biosciences to Host Conference Call on August 20th to Discuss Second Quarter 2014 Results and Provide Quarterly Update on Development Progress
GlobeNewswire - Mon Aug 18, 3:15PM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that management will host a conference call and live webcast to discuss second quarter 2014 financial results and provide an update on each of its development programs on Wednesday, August 20th at 5:00 PM ET.

Cellectar Biosciences Announces Pricing of $12,500,000 Public Offering and Listing on The Nasdaq Capital Market
GlobeNewswire - Thu Aug 14, 6:40PM CDT
Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced today the pricing of an underwritten public offering of 3,333,333 shares of its common stock at a per share price of $3.75 and warrants to purchase up to the same number of shares of common stock at a per warrant price of $0.01; plus the issuance of approximately an additional 1,110,000 shares and warrants in consideration of the cancellation of $4,000,000 principal amount of convertible debentures plus accrued interest. The warrants are exercisable immediately and expire five years from their date of issuance. The warrants will have an exercise price of $4.68 per share and will trade on the NASDAQ Capital Market under the symbol "CLRBW."

Cellectar Biosciences Files Investigational New Drug Application to Evaluate I-131-CLR1404 in Clinical Trials in Relapsed or Refractory Multiple Myeloma
GlobeNewswire - Mon Aug 11, 7:00AM CDT
Cellectar Biosciences, Inc. (OTCQX:CLRB), announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of I-131-CLR1404, a highly-selective, cancer-targeting radiopharmaceutical, in patients with relapsed/refractory multiple myeloma, an incurable cancer of plasma cells.

Cellectar Biosciences Announces 1-for-20 Reverse Stock Split and Reduction in Authorized Shares of Common Stock
GlobeNewswire - Fri Jun 13, 7:29AM CDT
Cellectar Biosciences, Inc. (OTCQX:CLRB), announced a 1-for-20 reverse stock split of its common stock, effective at the close of business today, as a first step in a planned listing of its common stock on the NASDAQ Capital Market.

Dr. Simon Pedder Becomes President and Chief Executive Officer of Cellectar Biosciences
GlobeNewswire - Wed Apr 02, 8:43AM CDT
Cellectar Biosciences, Inc. (OTCQX:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that effective April 1, 2014, Dr. Simon Pedder transitioned to President and CEO of Cellectar as planned following six months as acting chief executive officer. Dr. Pedder will continue to serve as a director.

Cellectar Biosciences Full-Year 2013 Financial Results and Recent Highlights
GlobeNewswire - Tue Mar 25, 3:30PM CDT
Cellectar Biosciences, Inc. (OTCQX:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, is providing an overview of its development programs and financial results for the year ended December 31, 2013.

Cellectar Biosciences to Host Conference Call on March 25th to Discuss Full Year 2013 Financial Results and Provide Quarterly Update on Development Progress
GlobeNewswire - Wed Mar 19, 7:54AM CDT
Cellectar Biosciences, Inc. (OTCQX:CLRB), a biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that management will host a conference call and live webcast to discuss full year 2013 financial results, provide an update on each of its development programs and discuss expectations for fiscal 2014 on Tuesday, March 25 at 5:00 PM ET.

Cellectar Announces Initiation of Phase II Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
GlobeNewswire - Tue Mar 04, 7:01AM CST
Cellectar Biosciences, Inc. (OTCQX:CLRB) a biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced enrollment of the first patient in its Phase II imaging trial of I-124-CLR1404 in patients with glioblastoma.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 100

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
Radiate Holdco's Q3 Results: What We Know Now

Updated Category News Views 117

Digging Into Third Quarter Highlights Radiate Holdco, LLC has just thrown its third-quarter financial hat into the ring, stirring up some interest in the world of FLFO secured notes and senior notes. The folks in Princeton, N.J., sure know how to keep things exclusive—this intel is only for those holding their Notes or in the pretty exclusive club of qualified...

Continue Reading
Texas Community Bancshares Adds a Special Dividend

Updated Category News Views 65

Nine cents is the whole message—for the moment Texas Community Bancshares has put a little extra cash on the table, declaring a regular quarterly dividend of $0.06 per common share and a special cash dividend of $0.03 per share. Together, holders get $0.09 per share, payable on or about December 15, 2026, provided they are shareholders of record when business closes on...

Continue Reading
Tenax Class Action: Investors Alley Fight for Redress

Updated Category News Views 288

Tenax Therapeutics in Hot Water Over Drug Trial Results Amidst the ever-unpredictable tides of the pharmaceutical industry, here comes a doozy – Tenax Therapeutics, Inc. is neck-deep in a shareholder lawsuit. If you tossed some money at NASDAQ:TENX anytime between November 13, 2023, and August 7, 2026, you might be feeling the sting of regret, and rightly so. What Went...

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 416

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 138

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading
Norris Lake's New Kayak Fleet Propels Tourism Efforts

Updated Category News Views 207

Norris Lake Doubles Down on Water Adventures The winds of change are paddling through Norris Dam State Park as they've launched a new fleet of shiny kayaks, hoping to lure more adventure seekers into the heart of Tennessee. These ain't just boats; they're part of a bigger play by local tourism honchos hungry to pump some adrenaline—and dollars—back into the area. A...

Continue Reading
Knotch Bets Brands Need Answers, Not More Web Pages

Updated Category News Views 102

Pages are starting to look like expensive filing cabinets A website that cannot answer an agent may soon be expensive wallpaper. That is the blunt premise behind Knotch's Ace for Agents, launched Nov. 17, 2026, and frankly it lands because plenty of big companies have spent years piling pages atop pages until nobody can tell which claim is current. Knotch is pitching an...

Continue Reading
Rakuten Medical Fires Up Phase 1 Trial for RM-0256 Therapy

Updated Category News Views 310

Taking Aim at Refractory Tumors in Japan Get this—Rakuten Medical is stepping into the ring with their new cancer-busting tactic, RM-0256 photoimmunotherapy, right in Japan. We're talking about a Phase 1 trial that'll throw a new kind of punch at solid tumors, specifically targeting troublesome skin cancers that don’t seem to play nice with current treatments. Now,...

Continue Reading
Kobo and CloudLibrary Make Library Ebooks Much Easier

Updated Category News Views 38

A tiny button can change whether a digital service gets used Borrowing an ebook ought not feel like assembling a radio in a dark garage, yet that is roughly where library reading has landed for plenty of people. OCLC's new CloudLibrary integration with Kobo strips out a particularly annoying step: U.S. and Canadian users can link accounts once, borrow a title, and have it...

Continue Reading

Top 5 Most Recently Viewed Articles

Taiwan Semiconductor's Arizona Facility Achieves First Profit

Updated Category News Views 276

Taiwan Semiconductor Celebrates Profit Milestone Taiwan Semiconductor Manufacturing Co. (NYSE: TSM) has made headlines with the profitable operation of its Arizona unit, marking a significant achievement. This milestone indicates robust performance, reinforcing its competitive position amidst increasing challenges from rivals like Samsung and Intel. Arizona Unit Sees...

Continue Reading
Greece Market Overview: Athens Composite Declines Amid Sector Losses

Updated Category News Views 54

Market Overview In the latest trading session, Greece's stock market faced a downturn, resulting in the Athens General Composite index experiencing a decline of 0.57%. This downturn was primarily influenced by poor performances across various sectors, notably Telecoms, Household, and Basic Resources. Such shifts in sector performance are vital indicators for investors...

Continue Reading
Charter Communications Adjusts Spectrum Internet Advertising Claims

Updated Category News Views 190

Charter Communications Adjusts Spectrum Internet Advertising Claims In a significant development for online advertising standards, Charter Communications, Inc. is adjusting its language regarding the claims made about Spectrum's internet service. The recommendation comes from the National Advertising Division (NAD) following a challenge raised by AT&T Services, Inc. The...

Continue Reading
Mitsubishi Electric Introduces High-Performance HVIGBT Modules

Updated Category News Views 252

Mitsubishi Electric to Launch New S1-Series HVIGBT Modules Mitsubishi Electric Corporation (TOKYO: 6503) has announced its plans to ship samples of two cutting-edge S1-Series High Voltage Insulated Gate Bipolar Transistor (HVIGBT) modules. These modules, rated at 1.7kV, are specifically engineered for large industrial applications including railcars and DC power...

Continue Reading
Celebrating Legacy: The Rich Passan Sports Writing Scholarship

Updated Category News Views 494

Introducing the Rich Passan Sports Writing Scholarship The National Press Club is excited to unveil the Rich Passan Sports Writing Scholarship, an annual commitment of $5,000 aimed at supporting aspiring undergraduate students who display outstanding talent and promise in sports journalism. This initiative embodies the dedication to nurturing young talent and upholding...

Continue Reading